AGP Executive Report
Last update: 9 hours agoBiotech: ImmunityBio says the first European patients have received Anktiva with BCG for bladder cancer. Its conditional approval covers Liechtenstein and the rest of the EU, though initial treatments were in Germany and Austria. Drug Development: Swiss firm Basilea will receive a $37.5 million milestone payment after strong European sales of its antifungal Cresemba, which is approved in Liechtenstein. Tech Partnerships: Liechtenstein joined its EFTA partners in a new Vietnam trade deal that opens the door to deeper science, technology and innovation cooperation. During a separate Liechtenstein state visit to India, space firm Open Cosmos also explored investment and partnerships in satellite technology and telecommunications.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.